Valuation: Kinarus Therapeutics Holding AG

Market Cap 4.72M 5.73M 5M 4.28M 8.01M 550M 8.05M 56.36M 21.79M 280M 21.55M 21.07M 900M P/E 2022
-0.23x
P/E 2023 -0.01x
Enterprise Value 4.71M 5.72M 4.99M 4.27M 8M 549M 8.04M 56.25M 21.74M 279M 21.51M 21.03M 898M EV / Sales 2022
4,318,722x
EV / Sales 2023 -
Free-Float
-
Yield 2022 *
-
Yield 2023 -
1 day+6.88%
Current month+25.25%
Current year+25.25%
3 years 0.9
Extreme 0.895999
33.15
5 years 0.9
Extreme 0.895999
230.27
10 years 0.9
Extreme 0.895999
230.27

Financials

2022 2023
Net sales 3.34 4.06 3.53 3.03 5.67 389.01 5.7 39.86 15.41 197.69 15.24 14.9 636.39 -
Net income -34.73M -42.23M -36.78M -31.54M -59M -4.05B -59.3M -415M -160M -2.06B -159M -155M -6.63B -49.38M -60.04M -52.3M -44.84M -83.88M -5.76B -84.31M -590M -228M -2.93B -226M -221M -9.42B
Net Debt 1.66M 2.02M 1.76M 1.51M 2.82M 193M 2.83M 19.81M 7.66M 98.25M 7.58M 7.41M 316M -9K -10.94K -9.53K -8.17K -15.29K -1.05M -15.37K -108K -41.57K -533K -41.12K -40.21K -1.72M
Logo Kinarus Therapeutics Holding AG
Kinarus Therapeutics Holding AG is a Switzerland-based Company that operates as a biopharmaceutical industry engaged in diseases treatment. The Company conducts its work within clinical-stage area and its activities include discovery, examination and development of medicines that are intended for the treatment of viral, respiratory, and ophthalmic diseases. Kinraus therapeutic drug is patent protected KIN001 which is a combination of pamapimod and pioglitazone. KIN0001 offers oral, long-term treatment of diseases with severe impact on the comfort of living.
Employees
-
Sector
-
Date Price Change
18/09/26 CHF 20.20 +6.88%
17/09/26 CHF 18.90 +5.59%
16/09/26 CHF 17.90 -5.79%
15/09/26 CHF 19.00 -2.31%
14/09/26 CHF 19.45 0.00%
  1. Stock Market
  2. Stocks
  3. CURE Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!